Dukes Prevents Class Cert. In Nexium MDL, AstraZeneca Says
By Dan Prochilo ( September 17, 2013, 2:40 PM EDT) -- AstraZeneca PLC and several generic-drug makers facing multidistrict antitrust litigation alleging they unlawfully delayed the market entry of a generic form of Nexium told a Massachusetts federal judge Monday that a "sprawling class" of the drug's third-party purchasers should not be certified in light of the Supreme Court's Wal-Mart Stores Inc. v. Dukes decision....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.